image
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
Pier Vincenzo Piazza, CEO
Latest News
Aelis Farma attended the first ICOD Symposium in Troina
March 2022
+
Aelis Farma announces the inclusion of the 1st patient in a phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD)
Juin 2022
+